At the Extraordinary General Meeting of NextCell Pharma AB (publ) ("NextCell" or the "Company") held on 21 August 2025, it was resolved that the Company shall change its financial year from a broken financial year September-August to a calendar year January-December. The Company's first full financial year in accordance with the calendar year will be 2026. To facilitate historical comparisons and enhance transparency for future reports that will follow the calendar year structure, the Company is today publishing financial information for the five most recent comparative quarters.
During the extended financial year 2024/2025, the following interim reports were published:
The Year-end Report 2025 for the period September 2024-December 2025 was NextCell Pharma's first interim report prepared in accordance with the calendar year structure. The quarter reported was October-December 2025 (accumulated September 2024-December 2025). The Q1 2026 report for the period January-March 2026 will be NextCell Pharma's first interim report under the ordinary calendar year structure and will be published on 28th of May 2026.
The summary of the comparison quarters contains no new information, other than a new quarterly breakdown based on the structure of the calendar year, derived from previously published data.
The report is available on the company's website.